Review Volume 11, Issue 13 pp 4757—4771
Circular RNAs in leukemia
- 1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
- 2 Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, China
- 3 Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China
- 4 The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
received: June 7, 2019 ; accepted: July 4, 2019 ; published: July 15, 2019 ;https://doi.org/10.18632/aging.102091
How to Cite
Copyright: Wu et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In pace with the development of gene sequencing technology and transcriptome research, it has been found that 70 to 90% of the human genome is transcribed into RNAs, while only 2% of RNAs encode proteins. This implies that non-coding RNAs (ncRNAs) may exert vital biological functions and a full analysis of non-coding transcriptomes is needed. Over the past decade, the advance in high-throughput sequencing and transcriptome profiling has enabled the identification of circular RNAs (circRNAs) involved in many biological processes and the occurrence and development of diseases. Accumulating evidence has revealed that circRNAs may serve as new biomarkers for diagnosis as well as provide promising therapeutic approaches and novel drug screening strategies for leukemia. A comprehensive understanding of circRNAs in leukemia is a prerequisite for the development of clinical translational research. In this review, we will discuss the general information of circRNAs and focus on the current advances in understanding the association between dysregulated circRNAs and leukemia.